Stockscreener 앱 받기
5.41
7.20%
-0.42
시간 외 거래:
5.41
전일 마감가:
$5.83
열려 있는:
$5.64
하루 거래량:
23,313
Relative Volume:
1.02
시가총액:
$125.49M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-19.37%
1개월 성능:
-23.59%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.41
$5.91
1주일 범위
$5.41
$7.40
52주 변동 폭
$5.41
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
명칭
Kalaris Therapeutics Inc
전화
(617) 433-2605
주소
1100 WINTER STREET, WALTHAM
KLRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
5.41 | 125.49M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | William Blair | Outperform |
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics restructures executive compensation By Investing.com - Investing.com South Africa
Kalaris Therapeutics restructures executive compensation - Investing.com
Kalaris Therapeutics Amends Executive Employment Agreements - TipRanks
Kalaris Therapeutics initiated with an Outperform at William Blair - MSN
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-The-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses - MarketScreener
William Blair initiates Kalaris stock with Outperform rating By Investing.com - Investing.com UK
William Blair Initiates Kalaris Therapeutics With Outperform Rating - marketscreener.com
Kalaris Therapeutics appoints new board chair By Investing.com - Investing.com Canada
The Gross Law Firm Notifies Shareholders of AlloVir, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of March 19, 2024(NASDAQ: ALVR) - MarketScreener
Kalaris Therapeutics appoints new board member - Investing.com Australia
Kalaris Therapeutics Appoints Leone Patterson to Board - TipRanks
Kalaris Therapeutics appoints new board member By Investing.com - Investing.com Canada
Kalaris Therapeutics appoints new board chair - Investing.com Australia
Kalaris Expands Board Of Directors Appointing Leone Patterson As Chair Of Audit Committee - marketscreener.com
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee - TradingView
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation - 01net
ALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - MarketScreener
ALVR Bronstein, Gewirtz & Grossman LLC Announces that AlloVir Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - MarketScreener
KLRS stock touches 52-week low at $7.75 amid market challenges - Investing.com
The Law Offices of Vincent Wong Remind AlloVir Investors of a Lead Plaintiff Deadline of March 19, 2024 - MarketScreener
ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionALVR - MarketScreener
Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact Levi & Korsinsky - MarketScreener
ALLOVIR SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options - Marketscreener.com
Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 - Investing.com India
Kalaris Therapeutics’ chief accounting officer sells shares worth $8,135 By Investing.com - Investing.com UK
Kalaris and AlloVir Inc. complete merger - Ophthalmology Times
Kalaris Therapeutics Announces Closing of Merger With AlloVir - VisionMonday.com
ALLOVIR, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts against AlloVir, Inc. - Marketscreener.com
Kalaris Therapeutics Completes Merger with AlloVir -March 19, 2025 at 04:18 am EDT - Marketscreener.com
AlloVir Merges with Kalaris Therapeutics, Inc. - TipRanks
Kalaris Therapeutics Completes Merger with AlloVir, Advances Phase 1 Trial of TH103 for Neovascular Retina Diseases - Nasdaq
Kalaris Secures $100M War Chest for Revolutionary Macular Degeneration Treatment - StockTitan
Shootin' the Bull about cattle feeders - The Globe and Mail
Kalaris and AlloVir Announce Stockholder Approval of Merger - VisionMonday.com
AlloVir shareholders approve merger with Kalaris Therapeutics By Investing.com - Investing.com India
Stockholders Approve Game-Changing Kalaris-AlloVir Merger: What This Means for Retinal Disease Treatment - StockTitan
Allovir, Inc. SEC 10-K Report - TradingView
Allovir’s chief accounting officer sells $967 in stock - Investing.com India
ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire
Allovir director Vikas Sinha sells $1,225 in stock - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, CYTH, ALVR on Behalf of Shareholders - Finansavisen
AlloVir executes reverse stock split - Investing.com
Allovir stock plunges to 52-week low, touches $0.4 - Investing.com
AlloVir announces reverse stock split effective January 16 - Investing.com
AlloVir shareholders approve reverse stock split - Investing.com
AlloVir appoints new CEO following leadership shakeup - Investing.com
Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead - insights.citeline.com
AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BioSpectrum Asia
Kalaris Therapeutics - The Pharma Letter
Kalaris to merge with AlloVir to become publicly traded company - World Pharmaceutical Frontiers
Kalaris Therapeutics Inc (KLRS) 재무 분석
Kalaris Therapeutics Inc (KLRS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):